Tesofensine vs Semaglutide

Tesofensine blocks reuptake of noradrenaline, dopamine and serotonin in the brain; semaglutide acts on GLP-1 receptors. They reduce appetite through unrelated mechanisms.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Tesofensine

A triple monoamine (noradrenaline, dopamine, serotonin) reuptake inhibitor that reduced weight in a phase 2 obesity trial.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

	Tesofensine	Semaglutide
The key difference	Central monoamine reuptake inhibitor	Peripheral and central GLP-1 agonist
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	By blocking reuptake of three monoamines, tesofensine suppresses appetite; animal work implicates α1-adrenoceptor and dopamine D1 pathways and silencing of GABAergic hypothalamic neurons.	Semaglutide is a GLP-1 analogue with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin, extending its half-life to about a week.
Status	Phase 2 obesity data (2008); further development has been limited. Not approved.	Approved medicine (type 2 diabetes and chronic weight management) in many countries, with a large phase 3 programme (STEP, SUSTAIN, SELECT). Prescription-only in South Africa.
Reported safety signals	Cardiovascular and psychiatric effects are the main questions for monoamine reuptake inhibitors; an abuse-potential study was run in recreational stimulant users.	Reviews document gastrointestinal effects as the most common; pancreatitis, gallbladder events and the effect on lean mass are active topics. Trials show weight regain after stopping.
A key study	A phase 2 trial measured body-weight change and safety with tesofensine in obesity. (Lancet 2008, PMID 18950853)	Reviews the safety profile of semaglutide across subcutaneous and oral formulations. (Front Endocrinol (Lausanne) 2021, PMID 34305810)

Semaglutide has the approval and outcome data; tesofensine is a mechanistic contrast from the reuptake-inhibitor class. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Tesofensine] Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial — Lancet 2008. PMID 18950853
[Tesofensine] Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat — Neuropsychopharmacology 2010. PMID 20200509
[Tesofensine] Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users — Clin Pharmacol Ther 2010. PMID 20520602
[Semaglutide] Safety of Semaglutide — Front Endocrinol (Lausanne) 2021. PMID 34305810
[Semaglutide] A systematic review of the effect of semaglutide on lean mass: insights from clinical trials — Expert Opin Pharmacother 2024. PMID 38629387
[Semaglutide] Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial — JAMA 2021. PMID 33755728

FREQUENTLY ASKED

What is the difference between Tesofensine and Semaglutide?

Tesofensine blocks reuptake of noradrenaline, dopamine and serotonin in the brain; semaglutide acts on GLP-1 receptors. They reduce appetite through unrelated mechanisms.

What is the regulatory status of Tesofensine and Semaglutide?

Tesofensine: Phase 2 obesity data (2008); further development has been limited. Not approved. Semaglutide: Approved medicine (type 2 diabetes and chronic weight management) in many countries, with a large phase 3 programme (STEP, SUSTAIN, SELECT). Prescription-only in South Africa.

What safety signals have been reported?

Tesofensine: Cardiovascular and psychiatric effects are the main questions for monoamine reuptake inhibitors; an abuse-potential study was run in recreational stimulant users. Semaglutide: Reviews document gastrointestinal effects as the most common; pancreatitis, gallbladder events and the effect on lean mass are active topics. Trials show weight regain after stopping.

Which studies is this comparison based on?

For Tesofensine: “Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial” (PMID 18950853); “Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat” (PMID 20200509); “Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users” (PMID 20520602). For Semaglutide: “Safety of Semaglutide” (PMID 34305810); “A systematic review of the effect of semaglutide on lean mass: insights from clinical trials” (PMID 38629387); “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial” (PMID 33755728).